HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM EBITDA Margin

EBITDA as a percentage of revenue.

HUTCHMED (China) LimitedNASDAQ: HCM

EBITDA Margin · Q2 FY2025 · quarter ended Jun 2025

EBITDA Margin widens to 0.9%

EBITDA Margin was 0.9% in Q2 FY2025, up 7.9 pp from a year earlier. On a trailing-twelve-month basis it was -1.2%, up 16.8 pp year over year. Over 3 fiscal years it widened by 86.5 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 16 analysts of 14.6% for the fiscal year ending Dec 2026, up from -7.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2025
0.9%+0.0 pp QoQ
Last fiscal yearDec 2025
-7.5%-2.5 pp YoY
LTMJun 2025
-1.2%+16.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.9 pp-87.2 pp-95.1 pp
1 year-2.5 pp+22.1 pp+24.7 pp
3 years+86.5 pp+24.2 pp-62.3 pp
5 years+27.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-7.5%
Year-over-year change
-2.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How HCM compares with its peers on the latest reported figures

  • HCM's LTM Jun 2025 EBITDA Margin of -1.2% is the 5th highest of the 11 companies compared; the peer median is -36.6%.
  • Its year-over-year change of +16.8 pp is the 3rd highest of 9, against a peer median of +6.2 pp.
  • Over three fiscal years its change of +86.5 pp compares with a peer median of +61.2 pp.
HCM Competitors Peer median
EBITDA Margin for HCM and competitors
Company Period LTM level YoY 3-year change
EXELExelixis, Inc.LTM Jul 202643.0% +6.3 pp+23.9 pp
INCYIncyte CorporationLTM Jun 202635.5% +6.0 pp+16.6 pp
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
HCMHUTCHMED (China) LimitedLTM Jun 2025-1.2% +16.8 pp+86.5 pp
BNTXBioNTech SELTM Jun 2026-35.6% -34.2 pp-98.4 pp
ZLABZai Lab LimitedLTM Jun 2026-37.5% +8.1 pp+167.8 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-60.1% +4260.2 pp+61.2 pp
AAPGAscentage Pharma Group InternationalFY2025-196.1% -171.8 pp+179.2 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-358.1% -250.5 pp+94.7 pp
ANLAdlai Nortye Ltd.LTM Jun 2024-979.5% ——
Peer median (excluding HCM) -36.6%+6.2 pp+61.2 pp

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.